Besides studying the impact of ERT on skeletal development, growth and remodeling, we utilized the Arsbm/m mice in order to establish an improved biomarker readout to monitor treatment efficacy in MPS-VI. Here, ELF3 is linked to mucopolysaccharidosis type 6.